ArticleViruses2019
Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol.
Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- [Treatment of bone and periprosthetic infections with bacteriophages : A systematic review].Der Orthopade · 2022Pooled it
- Model-dependent efficacy of sequential phage-antibiotic-antifungal therapy against dual-species biofilms.Biofilm · 2026Article
- 3D Printing of Bacteriophage-Loaded Hydrogels: Development of a Local and Long-Lasting Delivery System.Advanced healthcare materials · 2026Article
- Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Fracture-Related Infections: Current Status and Perspectives from the International Society of Antimicrobial Chemotherapy.Antibiotics (Basel, Switzerland) · 2025Review
- Editorial: Bacteriophage therapy in orthopedics-Key questions and emerging answers.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2025Article
- Prophage Activation: An In Silico Platform for Identifying Prophage Regulatory Elements to Inform Phage Engineering Against Drug-Resistant Bacteria.Life (Basel, Switzerland) · 2025Article
- Biocontrol of Phage Resistance inViruses · 2025Review
- Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.Antibiotics (Basel, Switzerland) · 2025Review
- Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.The Journal of clinical investigation · 2025Review
- Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.International journal of molecular sciences · 2025Review
- Phage Therapy for Orthopaedic Infections: The First Three Cases from the United Kingdom.Antibiotics (Basel, Switzerland) · 2025Article
- Current Strategies in the Prevention and Management of Infection in Open Fractures.Journal of orthopaedics and sports medicine · 2025Article
- Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Phage therapy as a revitalized weapon for treating clinical diseases.Microbiome research reports · 2025Review
- Phage diversity in One Health.Essays in biochemistry · 2024Review
- Challenges and opportunities of phage therapy forApplied and environmental microbiology · 2024Review
- Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophage therapy has recently attracted increased interest, particularly in difficult-to-treat infections. Although it is not a novel concept, standardized treatment guidelines are currently lacking. We present the first steps towards the establishment of a "multidisciplinary phage task force" (MPTF) and a standardized treatment pathway, based on our experience of four patients with severe musculoskeletal infections. After review of their medical history and current clinical status, a multidisciplinary team found four patients with musculoskeletal infections eligible for bacteriophage therapy within the scope of Article 37 of the Declaration of Helsinki. Treatment protocols were set up in collaboration with phage scientists and specialists. Based on the isolated pathogens, phage cocktails were selected and applied intraoperatively. A draining system allowed postoperative administration for a maximum of 10 days, 3 times per day. All patients received concomitant antibiotics and their clinical status was followed daily during phage therapy. No severe side-effects related to the phage application protocol were noted. After a single course of phage therapy with concomitant antibiotics, no recurrence of infection with the causative strains occurred, with follow-up periods ranging from 8 to 16 months. This study presents the successful outcome of bacteriophage therapy using a standardized treatment pathway for patients with severe musculoskeletal infection. A multidisciplinary team approach in the form of an MPTF is paramount in this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.